Alnylam Pharmaceuticals, Inc.

Alliance formed for intellectual property for RNAi therapeutics

Published in Pharma Investments, Ventures and Law Weekly, May 15th, 2005

Alnylam Pharmaceuticals, Inc., (ALNY), an RNAi therapeutics company, and Benitec, Ltd., (BLT), a developer of DNA-directed RNA interference therapeutics, announced a licensing agreement covering fundamental intellectual property (IP) in the field of RNA interference (RNAi).

Under the agreement, Alnylam will provide Benitec and its licensees an option to non-exclusively license Alnylam-controlled IP in the field of expressed RNAi: targeted gene silencing mediated by short interfering RNAs (siRNAs) generated from DNA constructs introduced into cells.

Upon Benitec's exercise of this option, Alnylam would receive license fees and be entitled to receive...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly

Source: Pharma Investments, Ventures and Law Weekly (2005-05-15)

More Articles from Pharma Investments, Ventures and Law Weekly

Adventrx Pharmaceuticals, Inc.
Pharmaceutical firm reports loss of $0.04 per share
Akzo Nobel
Pharmaceutical firm publishes full-year 2004 figures under IFRS rules
American Oriental Bioengineering, Inc.
Chinese pharmaceutical firm reports 53.2% increase in revenue
Andromed, Inc.
Diagnostics developer reports loss of $0.03 per share
Atrium Biotechnologies, Inc.
Biotech company raises $75 million
Avanir Pharmaceuticals
Pharmaceutical firm completes $17.1M sale of common stock
More from this issue of Pharma Investments, Ventures and Law Weekly

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry